Healthcare · NSE: RAINBOW
Rainbow Childrens Medicare
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 2 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹12,968Cr
- P/E
- 44.4×
- 1Y return
- −4.82%
- From 52W high
- −20.7%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 548 | 445 | +23.2% | 470 | +16.6% |
| EBITDA | 170 | 149 | +14.2% | 135 | +26.2% |
| EBITDA margin | 31.0% | 33.5% | -245 bps | 28.6% | +237 bps |
| PBTProfit before tax | 112 | 102 | +8.9% | 84 | +32.8% |
| Net profit | 82 | 75 | +9.1% | 61 | +35.5% |
| EPS (₹) | 8.10 | 7.41 | +9.3% | 5.97 | +35.7% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Blended payer mix expected at about 60:40
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 7
Blended payer mix expected at about 60:40
“In Tier 2 cities, where insurance penetration may be relatively lower, the overall mix will be different. On a blended basis, we expect the payer mix to be approximately 60:40.”
Stated revenue growth expectation remains high-teens
Abrarali Dalal · Group Chief Executive Officer · Q&A · p. 13
Stated revenue growth expectation remains high-teens
“Having said that, we remain optimistic about the growth outlook, but our stated expectation continues to be high-teens growth.”
Delhi NCR: Delhi NCR guidance to come three to six months before hospitals open
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 13
Delhi NCR: Delhi NCR guidance to come three to six months before hospitals open
“We will probably provide more specific guidance around six months or three months before the hospitals commence operations, as we have ambitious plans in terms of recruitment and how we intend to drive these hospitals.”
More figures from the call
“Normally, we indicate an ARPOB growth expectation of around 7%–8%. However, there can be periods when we witness higher growth due to a favourable case mix, increased contribution from obstetrics and the addition of fertility revenue.”
“There could be some margin pressure for a few quarters or even a year, perhaps in the range of 0.5% to 1%. However, this is manageable, particularly when you are already operating at a pre-Ind AS EBITDA margin of around 25%.”
“This is the backdrop to our guidance that we will continue to deliver pre-Ind AS EBITDA margins of around 25%.”
“During the quarter, we commenced operations at a newly acquired 70-bed hospital in Nellore and 50-bed brand-new hospital in Guntur.”
“We have 1,050 beds in pipeline at various stages of construction right now.”
In short
- 01Q2 FY27 revenue was Rs 548 crore, up 23.2%; EBITDA Rs 170 crore, up 14.2%; PAT Rs 83.9 crore, up 10.9%.
- 02Management guides pre-Ind AS EBITDA margin of around 25%-26% while expanding.
- 03Stated revenue growth expectation remains high-teens.
- 041,050 beds are under construction; about 2,300 beds are expected over the next three years.
- 05Malad opens Q1 FY28, Coimbatore and Gurugram Sector 56 in Q3 FY28, Gurugram Sector 44 hub in Q1 FY29.
- 06Expansion to be funded from internal cash flows and existing cash of Rs 542.8 crore.
- 07Drug price caps expected to have an insignificant impact, under 0.5% of margin.
Capex
Chennai: Chennai project, earlier delayed about six months, is back on track
6monthsRamesh Kancharla · Chairman and Managing Director · Q&A · p. 9
Chennai: Chennai project, earlier delayed about six months, is back on track
6months“We had earlier communicated a delay of approximately six months for Chennai. However, the project is now back on track.”
Delhi NCR: Delhi hospitals to start operations in phases to limit initial losses
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 18
Delhi NCR: Delhi hospitals to start operations in phases to limit initial losses
“We also intend to commence operations in phases so that we do not incur excessive initial operating losses.”
Capacity
Company working towards 5,000-plus beds from about 2,600 now
Abrarali Dalal · Group Chief Executive Officer · p. 5
Company working towards 5,000-plus beds from about 2,600 now
“Once again, keeping in mind our journey to 5,000-plus beds from the current 2,600-odd, we are transforming to a new HIS”
About 2,300 beds expected to be added over the next three years
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 13
About 2,300 beds expected to be added over the next three years
“We have another approximately 2,300 beds expected to be added over the next three years.”
Segments
mature hospitals: Mature hospital occupancy above 50% despite soft monsoon
Abrarali Dalal · Group Chief Executive Officer · p. 6
mature hospitals: Mature hospital occupancy above 50% despite soft monsoon
“Owing to all the initiatives mentioned, our mature hospitals have driven occupancies north of 50%, and robust revenue and EBITDA growth despite experiencing a soft monsoon and lesser seasonal diseases.”
new hospitals: Rajahmundry and Mahadevapura hospitals reached operational breakeven; Electronic City nearing it
Abrarali Dalal · Group Chief Executive Officer · p. 6
new hospitals: Rajahmundry and Mahadevapura hospitals reached operational breakeven; Electronic City nearing it
“Our new hospitals at Rajahmundry, AP, and Mahadevapura at Bengaluru have progressed well. Both have achieved operational breakeven. HRBR in Electronic City, the other new hospitals at Bengaluru are fast nearing the breakeven milestone.”
Hyderabad: New hospitals in Hyderabad cluster turn EBITDA positive in first year
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 12
Hyderabad: New hospitals in Hyderabad cluster turn EBITDA positive in first year
“For example, when we establish a new hospital within an existing cluster like Hyderabad, it is almost a given that it will generate positive EBITDA in the first year itself.”
new hospitals: New hospital category EBITDA margin around negative 16%
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 12
new hospitals: New hospital category EBITDA margin around negative 16%
“If you look at the new hospital category, while the revenue numbers are encouraging, the EBITDA margin is around negative 16%.”
mature hospitals: Mature hospital margins expected to hold, with possible further improvement
Abrarali Dalal · Group Chief Executive Officer · Q&A · p. 14
mature hospitals: Mature hospital margins expected to hold, with possible further improvement
“We remain optimistic of maintaining similar margins, with the possibility of some further improvement”
Demand
Q2 consultations up 19%, deliveries up 20%, inpatient discharges up 15%
Abrarali Dalal · Group Chief Executive Officer · p. 6
Q2 consultations up 19%, deliveries up 20%, inpatient discharges up 15%
“In terms of operational performance, patient consultations witnessed a growth of 19% compared to the quarter -- compared to the corresponding period last year. Deliveries grew by 20%, while inpatient discharges registered a growth of 15%.”
Tier 2 cities: Private insurance penetration about 30%-35% in Vijayawada and Rajahmundry
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 8
Tier 2 cities: Private insurance penetration about 30%-35% in Vijayawada and Rajahmundry
“For example, in locations such as Vijayawada and Rajahmundry, we are already witnessing private insurance penetration of around 30%–35%.”
Little seasonal business in last three quarters; growth from core paediatric and maternal care
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 9
Little seasonal business in last three quarters; growth from core paediatric and maternal care
“However, over the last three quarters, we have not witnessed much of the usual seasonal business. The performance has largely been driven by the underlying paediatric and maternal care business.”
H1 consultations up 21%, deliveries up 22%, inpatient discharges up 21%
Abrarali Dalal · Group Chief Executive Officer · p. 6
H1 consultations up 21%, deliveries up 22%, inpatient discharges up 21%
“For H1, outpatient consultations, deliveries and inpatient discharges grew by 21%, 22% and 21%, respectively, compared to the corresponding period of the previous financial year.”
Q2 described as seasonally soft due to lack of monsoon
Ramesh Kancharla · Chairman and Managing Director · p. 3
Q2 described as seasonally soft due to lack of monsoon
“We have delivered another quarter of robust growth, with healthy numbers from mature, emerging as well as new hospitals in inpatient volumes, outpatient footfalls as well as deliveries in a seasonally soft quarter because of a lack of monsoon.”
Margins and costs
EBITDA margin 31% in Q2 and 29.9% in H1
Abrarali Dalal · Group Chief Executive Officer · p. 6
EBITDA margin 31% in Q2 and 29.9% in H1
“The EBITDA margin for the current quarter stood at 31%, while for H1, the EBITDA margin was 29.9%.”
EBITDA margin about 30% post-Ind AS and 25% pre-Ind AS over last two years
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 7
EBITDA margin about 30% post-Ind AS and 25% pre-Ind AS over last two years
“Over the last two years, we have demonstrated that despite significant capacity additions, we have been able to deliver EBITDA margins of around 30% post-Ind AS and approximately 25% pre-Ind AS, without any significant margin pressure..”
Marketing spend a little over 2% of revenue; focus raised this year
Abrarali Dalal · Group Chief Executive Officer · Q&A · p. 10
Marketing spend a little over 2% of revenue; focus raised this year
“Our marketing expense is currently a little over 2% of revenue. We have significantly increased our focus on marketing this year and are exploring various channels, as I mentioned in my earlier remarks.”
Mature and emerging hospitals to keep generating EBITDA while new beds ramp up
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 7
Mature and emerging hospitals to keep generating EBITDA while new beds ramp up
“Of course, newly added beds will take some time to reach break-even. However, the hospitals in the emerging category, along with our mature hospitals, will continue to generate EBITDA and support the overall profitability of the business.”
Margins expected broadly stable, may improve slightly as new hospital losses fall
Abrarali Dalal · Group Chief Executive Officer · Q&A · p. 17
Margins expected broadly stable, may improve slightly as new hospital losses fall
“As the new hospitals move into the profitable stage or their operating losses reduce, our margins should broadly remain stable and may improve slightly.”
Debt and working capital
Cash, deposits and mutual funds of Rs 542.8 crore at 30 September 2026
Abrarali Dalal · Group Chief Executive Officer · p. 7
Cash, deposits and mutual funds of Rs 542.8 crore at 30 September 2026
“I'm pleased to inform you that the company's balance sheet remains robust with cash equivalents, fixed deposits and mutual fund investments aggregating to INR542.8 crores as of September 30, 2026.”
Expansion to be funded from business cash flows and existing cash
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 9
Expansion to be funded from business cash flows and existing cash
“The cash generated by the business, together with the existing cash balance on our balance sheet, should be adequate to fund our expansion plans.”
Acquisitions and new business
Highest valuation paid in past acquisitions about 11 times EV/EBITDA
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 17
Highest valuation paid in past acquisitions about 11 times EV/EBITDA
“I think, in the acquisitions we have undertaken so far, the maximum valuation we have paid has been around 11 times EV/EBITDA.”
No plan to buy adult hospitals; scope for inorganic expansion limited
Abrarali Dalal · Group Chief Executive Officer · Q&A · p. 17
No plan to buy adult hospitals; scope for inorganic expansion limited
“We would not be looking at acquiring adult hospitals and subsequently converting or integrating them into our model, as that would not be a viable approach. Therefore, the scope for inorganic expansion is relatively limited..”
New-city expansion to be partly organic, with a few acquisition opportunities
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 17
New-city expansion to be partly organic, with a few acquisition opportunities
“Some of these projects will be organic, and there are also a few opportunities in the market that could potentially work out for us.”
Management
New Group CFO Sudarshan Patodia onboarded; corporate management team complete
Abrarali Dalal · Group Chief Executive Officer · p. 5
New Group CFO Sudarshan Patodia onboarded; corporate management team complete
“Our managerial bandwidth at the corporate office is complete, with the onboarding of the new CFO.”
Risks
Project delays not expected to exceed two quarters
2quartersRamesh Kancharla · Chairman and Managing Director · Q&A · p. 9
Project delays not expected to exceed two quarters
2quarters“There could be some delays, but I would not expect them to exceed two quarters. In most cases, we have been able to deliver projects within a window of plus or minus one quarter of the planned timeline.”
Pharmacy cost about 14% of net revenue; about 7% is vaccines outside price caps
Abrarali Dalal · Group Chief Executive Officer · Q&A · p. 12
Pharmacy cost about 14% of net revenue; about 7% is vaccines outside price caps
“Pharmacy costs currently account for around 14% of Rainbow's net revenue, of which approximately 7% relates to vaccinations, which are not subject to these drug price caps.”
Under 0.5% of revenue exposed to drug price caps; impact called insignificant
Abrarali Dalal · Group Chief Executive Officer · Q&A · p. 12
Under 0.5% of revenue exposed to drug price caps; impact called insignificant
“Of the remaining 7%, less than 0.5% relates to oncology drugs and other medicines that could potentially come under the purview of price caps. Therefore, as we mentioned earlier, the impact of these price caps on Rainbow would be very insignificant.”
Any EBITDA margin compression from drug price caps seen well under 0.5%
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 16
Any EBITDA margin compression from drug price caps seen well under 0.5%
“I have not calculated the exact impact on EBITDA margins, but I am fairly confident that any compression would be much less than 0.5%.”
Competition mainly in obstetrics; children's business faces less competition
Ramesh Kancharla · Chairman and Managing Director · Q&A · p. 19
Competition mainly in obstetrics; children's business faces less competition
“If there is any degree of competition, it is largely in the obstetrics segment. Our children's healthcare business, however, is much larger and does not face the same level of competition.”
Other
Q2 operating revenue Rs 548 crore, up 23.2% year-on-year
Abrarali Dalal · Group Chief Executive Officer · p. 6
Q2 operating revenue Rs 548 crore, up 23.2% year-on-year
“Our operating revenue for the quarter stood at INR548 crores, reflecting a growth of 23.2% compared to the corresponding quarter of the previous financial year.”
Q2 EBITDA Rs 170 crore, up 14.2% year-on-year
Abrarali Dalal · Group Chief Executive Officer · p. 6
Q2 EBITDA Rs 170 crore, up 14.2% year-on-year
“Our EBITDA for the second quarter amounted to INR170 crores, marking a growth of 14.2% compared to the last year same period.”
Q2 PAT Rs 83.9 crore, up 10.9% year-on-year
Abrarali Dalal · Group Chief Executive Officer · p. 6
Q2 PAT Rs 83.9 crore, up 10.9% year-on-year
“Profit after tax for the quarter stood at INR83.9 crores, reflecting a growth of 10.9% compared to the corresponding quarter of the previous financial year.”
H1 revenue Rs 1,018 crore, up 27.6%
Abrarali Dalal · Group Chief Executive Officer · p. 6
H1 revenue Rs 1,018 crore, up 27.6%
“For H1, our revenue stood at INR1,018 crores, reflecting a growth of 27.6% compared to H1 of the previous financial year.”
H1 EBITDA Rs 304.6 crore, up 20.6%
Abrarali Dalal · Group Chief Executive Officer · p. 6
H1 EBITDA Rs 304.6 crore, up 20.6%
“For H1, our EBITDA stood at INR304.6 crores, reflecting a growth of 20.6% compared to H1 of the previous financial year.”
Sources
- Earnings call transcript, Q2 FY27 Filed 6 Nov 2026 · 20 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

